Suppr超能文献

立体定向心律失常消融(STAR):多学科联盟立体定向治疗折返性心动过速的标准化治疗和结果平台(STOPSTORM.eu),以及对欧洲当前 STAR 实践模式的回顾。

STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe.

机构信息

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Kiel 24105, Germany.

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.

出版信息

Europace. 2023 Apr 15;25(4):1284-1295. doi: 10.1093/europace/euac238.

Abstract

The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

摘要

由欧盟地平线 2020 框架资助的标准化治疗和立体定向治疗心动过速结果平台(STOPSTORM)联盟已经建立,作为一个大型研究网络,用于研究立体定向心律失常消融(STAR)治疗室性心动过速(VT)。其目的是提供一个汇集的治疗数据库,以评估 STAR 的实践模式和结果,并最终在欧洲协调 STAR。该联盟由 31 个临床和研究机构组成。该项目分为九个工作包(WPs):(i)观察队列;(ii)目标勾画的标准化和协调;(iii)协调的前瞻性队列;(iv)质量保证(QA);(v)分析和评估;(vi、ix)伦理和法规;以及(vii、viii)项目协调和传播。为了对欧洲目前的临床 STAR 实践进行综述,在项目开始时进行了全面的问卷调查。STOPSTORM 机构在 VT 导管消融(83%≥20 例)和立体定向体放射治疗(59%>200 例)方面的经验是充足的,在项目启动前已经进行了 84 例 STAR 治疗,而 8/22 个中心已经在国家临床试验中招募了 VT 患者。目前,大多数机构将其目标定义基于 VT 期间的映射(96%)和/或起搏映射(75%)、降低的电压区域(63%)或窦性节律期间的晚期心室电位(75%)。目前,大多数机构应用单次剂量 25 Gy,而计划技术和剂量处方方法差异很大。STOPSTORM 联盟目前的临床 STAR 实践强调了基质映射、目标勾画、运动管理、剂量测定和 QA 等方面的优化和协调潜力,这些将在各个 WP 中得到解决。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验